Literature DB >> 9694969

Regulation of cAMP-dependent protein kinase subunit expression in CATH.a and SH-SY5Y cells.

V A Boundy1, J Chen, E J Nestler.   

Abstract

Increasing evidence supports a role for adaptations in the cAMP pathway in mediating aspects of neural plasticity. These adaptations include altered levels of the catalytic (C) and regulatory (R) subunits of cAMP-dependent protein kinase (PKA) in specific neuronal cell types. In an effort to understand the mechanisms underlying this regulation of PKA, the effects of perturbing the cAMP pathway on PKA expression were examined in the locus ceruleus-like CATH.a cell line and the human neuroblastoma SH-SY5Y cell line. Exposure of CATH.a and SH-SY5Y cells to forskolin, a direct activator of adenylyl cyclase, resulted in a time-dependent decrease in levels of immunoreactivity of C and the two types of R (RI and RII). This decrease in PKA subunit immunoreactivity was not attenuated by pretreatment of the cells with the protein synthesis inhibitor cycloheximide. Moreover, exposure of the cell lines to forskolin had no effect on levels of mRNA for these PKA subunits over a wide time course. In contrast, treatment of cells with a cAMP antagonist (Rp-8-bromo-cAMPS) dramatically increased levels of PKA subunit immunoreactivity, particularly that of RI. No change in RI mRNA levels, however, was observed under these conditions. The PKA catalytic inhibitor H-89 did not attenuate the forskolin-induced down-regulation. The PKA subunit down-regulation was blocked, however, by treatment of the cells with Leu-Leu-Leu or lactacystin, inhibitors of proteasomes that are implicated in the regulated proteolysis of specific cellular proteins. Together, these findings demonstrate that regulation of PKA subunit expression by forskolin or a cAMP antagonist occurs primarily through post-transcriptional mechanisms and suggests the involvement of proteasome-mediated degradation in these phenomena.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694969

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Ubiquitin-mediated proteolysis in learning and memory.

Authors:  D G Chain; J H Schwartz; A N Hegde
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

2.  Knockdown of PRKAR1A, the gene responsible for Carney complex, interferes with differentiation in osteoblastic cells.

Authors:  Mei Zhang; Parmeet K Manchanda; Dayong Wu; Qianben Wang; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2014-02-07

Review 3.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

4.  Human tau may modify glucocorticoids-mediated regulation of cAMP-dependent kinase and phosphorylated cAMP response element binding protein.

Authors:  Yudong Liu; Ying Su; Shenggang Sun; Tao Wang; Xian Qiao; Hui Li; Xiaoqin Run; Zhihou Liang
Journal:  Neurochem Res       Date:  2012-05       Impact factor: 3.996

5.  GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism.

Authors:  Jessica J Hawes; Darlene H Brunzell; David Wynick; Venetia Zachariou; Marina R Picciotto
Journal:  J Neurochem       Date:  2005-06       Impact factor: 5.372

6.  Protein kinase A type I activates a CRE-element more efficiently than protein kinase A type II regardless of C subunit isoform.

Authors:  Øystein Stakkestad; Anja C V Larsen; Anne-Katrine Kvissel; Sissel Eikvar; Sigurd Ørstavik; Bjørn S Skålhegg
Journal:  BMC Biochem       Date:  2011-02-08       Impact factor: 4.059

7.  PKR Protects the Major Catalytic Subunit of PKA Cpk1 from FgBlm10-Mediated Proteasome Degradation in Fusarium graminearum.

Authors:  Chen Gong; Daiying Xu; Daiyuan Sun; Xue Zhang
Journal:  Int J Mol Sci       Date:  2022-09-06       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.